Rexahn Pharmaceuticals Inc (RNN)

0.22
0.00 0.18
AMEX : Health Care
Prev Close 0.22
Open 0.22
Day Low/High 0.21 / 0.22
52 Wk Low/High 0.24 / 0.65
Volume 984.02K
Avg Volume 607.30K
Exchange AMEX
Shares Outstanding 213.31M
Market Cap 46.93M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences

Rexahn Pharmaceuticals Strengthens Leadership Team

Rexahn Pharmaceuticals Strengthens Leadership Team

Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer

Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting

Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting

Data Show RX-3117, Archexin® and Supinoxin™ Appear to be Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Show Early Evidence of Clinical Activity

Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Important Clinical Progress in 2015 Highlights the Potential for Rexahn's Highly-Novel, Targeted Anti-Cancer Therapeutic Approach

8 Biotech Stocks Under $10 Poised for Breakouts

8 Biotech Stocks Under $10 Poised for Breakouts

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma

Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma

Evidence of Dose-Dependent Tumor Reduction Presented at Recent Medical Meetings

Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium

Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium

Additional Preclinical Data Continue to Support Evidence of the Anti-Cancer Effects of Supinoxin™ in Multiple Human Cancer Cell Models

New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Human Renal Cell Carcinoma

Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Phase IIa Clinical Data Presented at the ASCO 2016 Genitourinary Cancers Symposium

Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition

Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition

New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer

Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium

Rexahn Pharmaceuticals Reports Interim Clinical Data For Archexin® At The 14th International Kidney Cancer Symposium

Interim Data Show Archexin is Well Tolerated at the Doses Tested to Date With Early Evidence of Anti-Tumor Activity Observed in a Phase IIa Clinical Study in Metastatic Renal Cell Carcinoma

4 Stocks Under $10 Making Big Up Moves on Big Volume

4 Stocks Under $10 Making Big Up Moves on Big Volume

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Corporate Update

Interim Data Suggest Potential Clinical Activity of Supinoxin™ and RX-3117 Anti-Cancer Therapies

Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015

Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015

Supinoxin(TM) and RX-3117 Are Safe and Well Tolerated in Cancer Patients With Advanced and Metastatic Solid Tumors and Demonstrate Preliminary Evidence of Clinical Activity